Cranbury, New Jersey--IVIEW Therapeutics Inc., an innovative specialty biotechnology company committed to becoming a leader in ophthalmic therapeutics, announced the closing of its A+ round financing of approximately $25 million USD from both new and existing investors. This round was led by Proxima Ventures Fund, and also included new investors Cowin Capital, Ningbo Jiufeng Capital, Guangzhou Junyuan Capital, Hangzhou Naxin Capital, Haitian (HK) Co., PA Bioadvance, and existing investors including Shenzhen Share Capital, Zhejiang Huahai Pharmaceutical and Alpha Bioventure LLC.. This round was over-subscribed as its original plan aimed to raise $20 million dollars.

Dr. Bo Liang, Chairman & CEO at IVIEW commented, "I am glad that the investors, both new and existing participants, have confidence in IVIEW’s team, its ophthalmic drug delivery platform technologies and product pipeline. We plan to use the proceeds from this round of investment to complete IVIEW-1201’s global phase II trials, as a potential first-line treatment of viral conjunctivitis, and to advance the company’s preclinical assets into clinical development for dry eye and the treatment of cataracts. IVIEW is also aggressively pursuing business development opportunities for innovative developmental assets.

“We are happy to lead this round of investment into IVIEW Therapeutics, followed by other reputable venture groups. We are impressed by IVIEW’s team and its product pipeline to bring various ophthalmic products to clinical development. We hope the company will invest in innovative products to fulfill unmet medical needs.” Commented by Mr. Luke Sun, Founding Partner of Proxima Venture.

About IVIEW Therapeutics Inc.

IVIEW Therapeutics Inc. is a clinical-stage specialty biotechnology company focusing on innovative ophthalmic therapeutics. IVIEW is headquartered at 5 Cedar Brook Drive, Cranbury, NJ (the greater-Princeton area). IVIEW was founded by experienced pharmaceutical veterans and clinical ophthalmologists to help patients by bringing novel ophthalmic drug products to market to address unmet medical needs. Please visit: www.iviewtherapeutics.com for more details.